Screening for hyperglycemia in the developing world: Rationale, challenges and opportunities

Diabetes Research and Clinical Practice

Volumn 98, Issue 2, 2012, Pages 199-208

  Echouffo Tcheugui, Justin B ^a   Mayige, Mary ^b,g   Ogbera, Anthonia Okeoghene ^c   Sobngwi, Eugene ^b   Kengne, Andre P ^d,e,f  

^a EMORY UNIVERSITY   (United States)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c LAGOS STATE UNIVERSITY TEACHING HOSPITAL   (Nigeria)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

Author keywords

Developing countries; Diabetes mellitus; Prediabetes; Screening

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

BLOOD GLUCOSE MONITORING; CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DISEASE ASSOCIATION; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; FUNDING; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HEALTH CARE POLICY; HUMAN; HYPERGLYCEMIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATIENT ASSESSMENT; REVIEW; RISK ASSESSMENT; SCREENING TEST; STAFF TRAINING;

COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; HUMANS; HYPERGLYCEMIA; MASS SCREENING;

EID: 84870549975     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.08.003     Document Type: Review

References (93)

1. Whiting D.R., Guariguata L., Weil C., Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011, 94:311-321.
2. Engelgau M.M., Geiss L.S., Saaddine J.B., Boyle J.P., Benjamin S.M., Gregg E.W., et al. The evolving diabetes burden in the United States. Ann Intern Med 2004, 140:945-950.
3. Roglic G., Unwin N. Mortality attributable to diabetes: estimates for the year 2010. Diabetes Res Clin Pract 2010, 87:15-19.
4. Norris S.L., Kansagara D., Bougatsos C., Fu R. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2008, 148:855-868.
5. Echouffo-Tcheugui J.B., Ali M.K., Griffin S.J., Narayan K.M. Screening for type 2 diabetes and dysglycemia. Epidemiol Rev 2011, 33:63-87.
6. Crandall J.P., Knowler W.C., Kahn S.E., Marrero D., Florez J.C., Bray G.A., et al. The prevention of type 2 diabetes. Nat Clin Pract 2008, 4:382-393.
7. Gillies C.L., Abrams K.R., Lambert P.C., Cooper N.J., Sutton A.J., Hsu R.T., et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007, 334:299.
8. Wilson J.M.G., Junger G. Principles and practice of screening for disease 1968, World Health Organization, Geneva.
9. Danaei G., Finucane M.M., Lu Y., Singh G.M., Cowan M.J., Paciorek C.J., et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011, 378:31-40.
10. Yang W., Lu J., Weng J., Jia W., Ji L., Xiao J., et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010, 362:1090-1101.
11. Gu K., Cowie C.C., Harris M.I. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care 1998, 21:1138-1145.
12. Danaei G., Lawes C.M., Vander Hoorn S., Murray C.J., Ezzati M. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet 2006, 368:1651-1659.
13. Gregg E.W., Gu Q., Williams D., de Rekeneire N., Cheng Y.J., Geiss L., et al. Prevalence of lower extremity diseases associated with normal glucose levels, impaired fasting glucose, and diabetes among U.S. adults aged 40 or older. Diabetes Res Clin Pract 2007, 77:485-488.
14. Saaddine J.B., Narayan K.M., Engelgau M.M., Aubert R.E., Klein R., Beckles G.L. Prevalence of self-rated visual impairment among adults with diabetes. Am J Public Health 1999, 89:1200-1205.
15. Garduno-Diaz S.D., Khokhar S. Prevalence, risk factors and complications associated with type 2 diabetes in migrant South Asians. Diabetes Metab Res Rev 2012, 28:6-24.
16. International Diabetes Federation IDF diabetes atlas 2011, International Diabetes Federation, Brussels, Belgium. 5th ed.
17. DECODE Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 1999, 354:617-621.
18. Sorkin J.D., Muller D.C., Fleg J.L., Andres R. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore longitudinal study of aging with a critical review of the literature. Diabetes Care 2005, 28:2626-2632.
19. Nakagami T. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004, 47:385-394.
20. Saydah S.H., Loria C.M., Eberhardt M.S., Brancati F.L. Subclinical states of glucose intolerance and risk of death in the US. Diabetes Care 2001, 24:447-453.
21. Barr E.L., Boyko E.J., Zimmet P.Z., Wolfe R., Tonkin A.M., Shaw J.E. Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) Study. Diabetologia 2009, 52:415-424.
22. Barr E.L., Zimmet P.Z., Welborn T.A., Jolley D., Magliano D.J., Dunstan D.W., et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007, 116:151-157.
23. Wen C.P., Cheng T.Y., Tsai S.P., Hsu H.L., Wang S.L. Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan. Diabetes Care 2005, 28:2756-2761.
24. Ford E.S., Zhao G., Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol 2010, 55:1310-1317.
25. Milman S., Crandall J.P. Mechanisms of vascular complications in prediabetes. Med Clin North Am 2011, 95:309-325. vii.
26. Zhang Y., Dall T.M., Chen Y., Baldwin A., Yang W., Mann S., et al. Medical cost associated with prediabetes. Popul Health Manage 2009, 12:157-163.
27. Zhang P., Zhang X., Brown J., Vistisen D., Sicree R., Shaw J., et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87:293-301.
28. Barcelo A., Aedo C., Rajpathak S., Robles S. The cost of diabetes in Latin America and the Caribbean. Bull World Health Organ 2003, 81:19-27.
29. McEwen L.N., Karter A.J., Curb J.D., Marrero D.G., Crosson J.C., Herman W.H. Temporal trends in recording of diabetes on death certificates: results from Translating Research Into Action for Diabetes (TRIAD). Diabetes Care 2011, 34:1529-1533.
30. Bertram M.Y., Vos T. Quantifying the duration of pre-diabetes. Aust N Z J Public Health 2010, 34:311-314.
31. Harris M.I., Klein R., Welborn T.A., Knuiman M.W. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992, 15:815-819.
32. Gerstein H.C., Santaguida P., Raina P., Morrison K.M., Balion C., Hunt D., et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007, 78:305-312.
33. Ramachandran A., Snehalatha C., Mary S., Mukesh B., Bhaskar A.D., Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006, 49:289-297.
34. Engelgau M.M., Narayan K.M., Herman W.H. Screening for type 2 diabetes. Diabetes Care 2000, 23:1563-1580.
35. Borch-Johnsen K., Lauritzen T., Glumer C., Sandbaek A. Screening for type 2 diabetes-should it be now?. Diabet Med 2003, 20:175-181.
36. Buijsse B., Simmons R.K., Griffin S.J., Schulze M.B. Risk assessment tools for identifying individuals at risk of developing type 2 diabetes. Epidemiol Rev 2011, 33:46-62.
37. Noble D., Mathur R., Dent T., Meads C., Greenhalgh T. Risk models and scores for type 2 diabetes: systematic review. BMJ 2011, 343:d7163.
38. Thoopputra T., Newby D., Schneider J., Li S.C. Survey of diabetes risk assessment tools: concepts, structure and performance. Diabetes Metab Res Rev 2012, 10.1002/dmrr.2296.
39. Janipalli C.S., Kumar M.V., Vinay D.G., Sandeep M.N., Bhaskar S., Kulkarni S.R., et al. Analysis of 32 common susceptibility genetic variants and their combined effect in predicting risk of type 2 diabetes and related traits in Indians. Diabet Med 2012, 29:121-127.
40. Moons K.G., Kengne A.P., Woodward M., Royston P., Vergouwe Y., Altman D.G., et al. Risk prediction models. I. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart 2012, 98:683-690.
41. Moons K.G., Kengne A.P., Grobbee D.E., Royston P., Vergouwe Y., Altman D.G., et al. Risk prediction models. II. External validation, model updating, and impact assessment. Heart 2012, 98:691-698.
42. Vistisen D., Lee C.M., Colagiuri S., Borch-Johnsen K., Glumer C. A globally applicable screening model for detecting individuals with undiagnosed diabetes. Diabetes Res Clin Pract 2012, 95:432-438.
43. Ziemer D.C., Kolm P., Foster J.K., Weintraub W.S., Vaccarino V., Rhee M.K., et al. Random plasma glucose in serendipitous screening for glucose intolerance: screening for impaired glucose tolerance study 2. J Gen Intern Med 2008, 23:528-535.
44. Saudek C.D., Herman W.H., Sacks D.B., Bergenstal R.M., Edelman D., Davidson M.B. A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab 2008, 93:2447-2453.
45. Kim K.S., Kim S.K., Lee Y.K., Park S.W., Cho Y.W. Diagnostic value of glycated haemoglobin HbA(1c) for the early detection of diabetes in high-risk subjects. Diabet Med 2008, 25:997-1000.
46. Cheng C., Kushner H., Falkner B.E. The utility of fasting glucose for detection of prediabetes. Metabolism 2006, 55:434-438.
47. Standards of medical care in diabetes-2012. Diabetes Care 2012, 35(Suppl. 1):S11-S63.
48. Report of a World Health Organization Consultation: use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Diabetes Res Clin Pract 2011, 93:299-309.
49. Carson A.P., Reynolds K., Fonseca V.A., Muntner P. Comparison of A1C and fasting glucose criteria to diagnose diabetes among U.S. adults. Diabetes Care 2010, 33:95-97.
50. Lorenzo C., Haffner S.M. Performance characteristics of the new definition of diabetes: the insulin resistance atherosclerosis study. Diabetes Care 2010, 33:335-337.
51. Cowie C.C., Rust K.F., Byrd-Holt D.D., Gregg E.W., Ford E.S., Geiss L.S., et al. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006. Diabetes Care 2010, 33:562-568.
52. Kramer C.K., Araneta M.R., Barrett-Connor E. A1C and diabetes diagnosis: the Rancho Bernardo study. Diabetes Care 2010, 33:101-103.
53. Christensen D.L., Witte D.R., Kaduka L., Jorgensen M.E., Borch-Johnsen K., Mohan V., et al. Moving to an A1C-based diagnosis of diabetes has a different impact on prevalence in different ethnic groups. Diabetes Care 2010, 33:580-582.
54. Herman W.H., Cohen R.M. Racial and ethnic differences in the relationship between HbA1c and blood glucose: implications for the diagnosis of diabetes. J Clin Endocrinol Metab 2012, 97:1067-1072.
55. John W.G., Mosca A., Weykamp C., Goodall I. HbA1c standardisation: history, science and politics. Clin Biochem Rev 2007, 28:163-168.
56. Gomez-Perez F.J., Aguilar-Salinas C.A., Almeda-Valdes P., Cuevas-Ramos D., Lerman Garber I., Rull J.A. HbA1c for the diagnosis of diabetes mellitus in a developing country. A position article. Arch Med Res 2010, 41:302-308.
57. Sacks D.B., Bruns D.E., Goldstein D.E., Maclaren N.K., McDonald J.M., Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002, 48:436-472.
58. Ko G.T., Chan J.C., Woo J., Lau E., Yeung V.T., Chow C.C., et al. The reproducibility and usefulness of the oral glucose tolerance test in screening for diabetes and other cardiovascular risk factors. Ann Clin Biochem 1998, 35(Pt 1):62-67.
59. Priya M., Mohan Anjana R., Pradeepa R., Jayashri R., Deepa M., Bhansali A., et al. Comparison of capillary whole blood versus venous plasma glucose estimations in screening for diabetes mellitus in epidemiological studies in developing countries. Diabetes Technol Ther 2011, 13:586-591.
60. Rush E., Crook N., Simmons D. Point-of-care testing as a tool for screening for diabetes and pre-diabetes. Diabet Med 2008, 25:1070-1075.
61. Ritchie G.E., Kengne A.P., Joshi R., Chow C., Neal B., Patel A., et al. Comparison of near-patient capillary glucose measurement and a risk assessment questionnaire in screening for type 2 diabetes in a high-risk population in rural India. Diabetes Care 2011, 34:44-49.
62. Phillips L.S., Ziemer D.C., Kolm P., Weintraub W.S., Vaccarino V., Rhee M.K., et al. Glucose challenge test screening for prediabetes and undiagnosed diabetes. Diabetologia 2009, 52:1798-1807.
63. Griffin S.J., Borch-Johnsen K., Davies M.J., Khunti K., Rutten G.E., Sandbaek A., et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011, 378:156-167.
64. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393.
65. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
66. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998, 317:703-713.
67. Costa J., Borges M., David C., Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006, 332:1115-1124.
68. Turnbull F., Neal B., Algert C., Chalmers J., Chapman N., Cutler J., et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005, 165:1410-1419.
69. Wing R.R., Lang W., Wadden T.A., Safford M., Knowler W.C., Bertoni A.G., et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011, 34:1481-1486.
70. Walley J., Lawn J.E., Tinker A., de Francisco A., Chopra M., Rudan I., et al. Primary health care: making Alma-Ata a reality. Lancet 2008, 372:1001-1007.
71. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
72. Pan X.R., Li G.W., Hu Y.H., Wang J.X., Yang W.Y., An Z.X., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997, 20:537-544.
73. Knowler W.C., Fowler S.E., Hamman R.F., Christophi C.A., Hoffman H.J., Brenneman A.T., et al. 10-Year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374:1677-1686.
74. Li G., Zhang P., Wang J., Gregg E.W., Yang W., Gong Q., et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008, 371:1783-1789.
75. Balagopal P., Kamalamma N., Patel T.G., Misra R. A community-based diabetes prevention and management education program in a rural village in India. Diabetes Care 2008, 31:1097-1104.
76. Oba N., McCaffrey R., Choonhapran P., Chutug P., Rueangram S. Development of a community participation program for diabetes mellitus prevention in a primary care unit, Thailand. Nurs Health Sci 2011, 13:352-359.
77. Ali M.K., Echouffo-Tcheugui J., Williamson D.F. How effective were lifestyle interventions in real-world settings that were modeled on the Diabetes Prevention Program?. Health Aff 2012, 31:67-75.
78. Kiawi E., Edwards R., Shu J., Unwin N., Kamadjeu R., Mbanya J.C. Knowledge, attitudes, and behavior relating to diabetes and its main risk factors among urban residents in Cameroon: a qualitative survey. Ethn Dis 2006, 16:503-509.
79. Weber M.B., Ranjani H., Meyers G.C., Mohan V., Narayan K.M. A model of translational research for diabetes prevention in low and middle-income countries: the Diabetes Community Lifestyle Improvement Program (D-CLIP) trial. Prim Care Diabetes 2012, 6:3-9.
80. Schellhase K.G., Koepsell T.D., Weiss N.S., Wagner E.H., Reiber G.E. Glucose screening and the risk of complications in type 2 diabetes mellitus. J Clin Epidemiol 2003, 56:75-80.
81. Schneider H., Ehrlich M., Lischinnski M. Did the intensive glycosuria screening of the sixties and seventies in East Germany improve the survival prognosis of early detected diabetics?. Diabetes Stoffweschsel 1996, 5:33-38.
82. Echouffo-Tcheugui J.B., Simmons R.K., Williams K.M., Barling R.S., Prevost A.T., Kinmonth A.L., et al. The ADDITION-Cambridge trial protocol-a cluster randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients. BMC Public Health 2009, 9:136.
83. Giel K.E., Enck P., Zipfel S., Schrauth M., Bury A., Graf M., et al. Psychological effects of prevention: do participants of a type 2 diabetes prevention program experience increased mental distress?. Diabetes Metab Res Rev 2009, 25:83-88.
84. Waugh N., Scotland G., McNamee P., Gillett M., Brennan A., Goyder E., et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess 2007, 11:1-125. iii-iv, ix-xi.
85. Kahn R., Alperin P., Eddy D., Borch-Johnsen K., Buse J., Feigelman J., et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 2010, 375:1365-1374.
86. Castro-Rios A., Doubova S.V., Martinez-Valverde S., Coria-Soto I., Perez-Cuevas R. Potential savings in Mexico from screening and prevention for early diabetes and hypertension. Health Aff 2010, 29:2171-2179.
87. Toscano C.M., Duncan B.B., Mengue S.S., Polanczyk C.A., Nucci L.B., Costa e Forti A., et al. Initial impact and cost of a nationwide population screening campaign for diabetes in Brazil: a follow up study. BMC Health Serv Res 2008, 8:189.
88. Nucci L.B., Toscano C.M., Maia A.L., Fonseca C.D., Britto M.M., Duncan B.B., et al. A nationwide population screening program for diabetes in Brazil. Rev Panam Salud Publica 2004, 16:320-327.
89. Sargeant L.A., Simmons R.K., Barling R.S., Butler R., Williams K.M., Prevost A.T., et al. Who attends a UK diabetes screening programme? Findings from the ADDITION-Cambridge study. Diabet Med 2010, 27:995-1003.
90. Colagiuri S., Hussain Z., Zimmet P., Cameron A., Shaw J. Screening for type 2 diabetes and impaired glucose metabolism: the Australian experience. Diabetes Care 2004, 27:367-371.
91. Klein Woolthuis E.P., de Grauw W.J., van Gerwen W.H., van den Hoogen H.J., van de Lisdonk E.H., Metsemakers J.F., et al. Yield of opportunistic targeted screening for type 2 diabetes in primary care: the diabscreen study. Ann Fam Med 2009, 7:422-430.
92. World Health Organization. Screening for type 2 diabetes. Report of a World Health Organization and International Diabetes Federation meeting. Geneva; 2003.
93. IDF clinical guidelines task force. Global guideline for type 2 diabetes 2005, International Diabetes Federation, Brussels.